Johns Hopkins ABX Guide
Vosevi
INDICATIONS
FDA
FDA
- Treatment of adult patients with chronic HCV infection without cirrhosis or compensated cirrhosis (Child-Pugh A) who have:
- Genotype 1, 2, 3, 4, 5 or 6 infection who have previously been treated with an HCV regimen containing an NS5A inhibitor
- Genotype 1a or 3 infection and have been previously treated with sofosbuvir without an NS5A inhibitor
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: June 4, 2018
Citation
Dzintars, Kathryn. "Vosevi." Johns Hopkins ABX Guide, The Johns Hopkins University, 2018. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540689/all/Vosevi.
Dzintars K. Vosevi. Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540689/all/Vosevi. Accessed December 3, 2024.
Dzintars, K. (2018). Vosevi. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540689/all/Vosevi
Dzintars K. Vosevi [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. [cited 2024 December 03]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540689/all/Vosevi.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Vosevi
ID - 540689
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2018/06/04/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540689/all/Vosevi
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
